SPECIALIZED PGM OF RESEARCH EXCELLENCE/PROSTATE CANCER

  • Rodriguez, Ronald (PI)
  • De Marzo, Angelo (PI)
  • Yegnasubramanian, Srinivasan (PI)
  • Drake, Charles (PI)
  • Getzenberg, Robert (PI)
  • Pili, Roberto (PI)
  • Platz, Elizabeth A. (PI)
  • Lupold, Shawn (PI)
  • Trock, Bruce (PI)
  • Pomper, Martin (PI)
  • Partin, Alan (PI)
  • Carducci, Michael A. (PI)
  • Simons, Jonathan (PI)
  • Pardoll, Drew (PI)
  • Carter, Ballentine (PI)
  • Barrack, Evelyn (PI)
  • Reddi, A. Hari (PI)
  • Coffey, Donald (PI)
  • Isaacs, William (PI)
  • Piantadosi, Steven (PI)
  • Epstein, Jonathan (PI)
  • Nelson, William George (PI)
  • Isaacs, John T. (PI)

Project: Research project

Description

This SPORE application (P-50) is to support a highly interactive and
multidisciplinary study at the Johns Hopkins Medical Institutions to impact
on control of human prostate cancer. This SPORE involves 18 interactive
components that can be categorized into: A.) Studies of the Molecular and
Cellular Mechanisms in Human Prostate Cancer. 1.) Molecular genetic
studies (W. Isaacs); 2.) Familial studies to identify genetic linkages (T.
Beaty/P. Walsh/W. Isaacs); 3.) High resolution cytogenetic studies (C.
Griffin); 4.) Molecular analysis of androgen receptor gene structure and
function (E. Barrack); 5.) Molecular mechanisms in prostate cancer bone
metastasis (H. Reddi); 6.) Studies of nuclear structure and DNA
organization (D. Coffey). B. Early Human Prostate Cancer Detection and
Prediction Studies: 7.) Identification of men at risk for prostate cancer
(B. Carter/J. Fozard); 8.) Quantitative pathology to predict clinical
outcome (J. Epstein); 9.) Identification of metastatic suppressor genes (J.
Isaacs). C. Development of New Therapies. 10.) Identification of new
topoisomerase drug targets (W. Nelson/L. Liu); 11.) Prostate cancer gene
targeted immunotherapy in animal models (D. Pardoll/R. Mulligan); 12.) Gene
transfer therapy in human prostate cancer cells (J. Simons/R. Mulligan);
13.) Development of new transgenic models of prostate cancer and prostate
autoimmunity (D. Pardoll/W. Nelson); D. Development of Special Resources.
14.) New animal xenograft models of human prostate cancer (J. Isaacs); 15.)
Establishment of a prostate cancer tissue and DNA bank (J. Epstein/W.
Isaacs); 16.) Biostatistical core for prostate cancer studies (S.
Piantadosi); 17.) Formation of a communication and education unit for the
rapid national dissemination of research information on prostate cancer and
for a national summer course on prostate research (D. Coffey). 18.) Pilot
Project Development to a.) study viral aspects of prostate cancer (W.
Burns) and b.) NMR spectroscopy studies of programmed cell death in
prostate cancer (J. Glickson). These multidisciplinary programs extend from familial studies to employing
new methods in gene therapy utilizing human prostate cancer cells in close
collaboration with Dr. Richard Mulligan at MIT. These 18 components of the
SPORE will focus primarily on human prostate cancer, differing from a
Program Project Grant as each unit is designed to be both highly
interactive and dependent on other programs within the SPORE. The program
is designed to facilitate the rapid translation of these findings into the
control of human prostate cancer.
StatusActive
Effective start/end date9/30/928/31/19

Funding

  • National Institutes of Health

Fingerprint

Genetic Therapy
Prostatic Neoplasms
Animal Models
Tissue Banks
Suppressor Genes
Genetic Linkage
Information Dissemination
Androgen Receptors
Research
Heterografts
Cytogenetics
Immunotherapy
Prostate
Cell Death
Magnetic Resonance Spectroscopy

ASJC

  • Medicine(all)